Faculty Collaboration Database

Medical College of Wisconsin

CTSI Cores Search Research Informatics REDCap

Kenneth Brian Gordon MD

Chair, Professor

Institution: Medical College of Wisconsin
Department: Dermatology
Program: Administration

Send Message

Request Meeting

View Curriculum Vitae

Publications (218)

Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical Trial. (Papp KA, Gordon K, Strober B, Zhuo J, Becker B, Zhong Y, Beaumont JL, Pham TP, Kisa R, Napoli AA, Banerjee S, Armstrong AW) JAMA Dermatol 2024 Feb 01;160(2):204-209 PMID: 38117487 PMCID: PMC10733845 SCOPUS ID: 2-s2.0-85180996904 12/20/2023

Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review (Blauvelt A, Langley RG, Gordon KB, Silverberg JI, Eyerich K, Sommer MOA, Felding J, Warren RB) Dermatology and Therapy December 2023;13(12):3031-3042 SCOPUS ID: 2-s2.0-85175655223 12/01/2023 2 Citations

Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. (Morita A, Strober B, Burden AD, Choon SE, Anadkat MJ, Marrakchi S, Tsai TF, Gordon KB, Thaçi D, Zheng M, Hu N, Haeufel T, Thoma C, Lebwohl MG) Lancet 2023 Oct 28;402(10412):1541-1551 PMID: 37738999 SCOPUS ID: 2-s2.0-85173148730 09/23/2023 18 Citations

Methotrexate for inflammatory skin disease in pediatric patients: Consensus treatment guidelines. (Siegfried EC, Arkin LM, Chiu YE, Hebert AA, Callen JP, Castelo-Soccio L, Co DO, Cordoro KM, Curran ML, Dalrymple AM, Flohr C, Gordon KB, Hanna D, Irvine AD, Kim S, Kirkorian AY, Lara-Corrales I, Lindstrom J, Paller AS, Reyes M, Begolka WS, Tom WL, Van Voorhees AS, Vleugels RA, Lee LW, Davies OMT, Brandling-Bennett HA) Pediatr Dermatol 2023;40(5):789-808 PMID: 37316462 SCOPUS ID: 2-s2.0-85161815440 06/15/2023 6 Citations

Differentiating biologics to prevent psoriatic arthritis in patients with psoriasis – Authors' reply (Singla S, Putman M, Liew J, Gordon K) The Lancet Rheumatology June 2023;5(6):e313 SCOPUS ID: 2-s2.0-85159612732 06/01/2023

Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary. (Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, Rich P, Paul C, Bagel J, Colston E, Throup J, Kundu S, Sekaran C, Linaberry M, Banerjee S, Papp KA) Immunotherapy 2023 Aug;15(11):787-797 PMID: 37150956 SCOPUS ID: 2-s2.0-85161651265 05/08/2023 2 Citations

Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study (Singla S, Putman M, Liew J, Gordon K) The Lancet Rheumatology April 2023;5(4):e200-e207 SCOPUS ID: 2-s2.0-85150252036 04/01/2023 15 Citations

Deucravacitinib in moderate-to-severe psoriasis. (Vu A, Maloney V, Gordon KB) Immunotherapy 2022 Nov;14(16):1279-1290 PMID: 36373503 SCOPUS ID: 2-s2.0-85142918537 11/15/2022 2 Citations

Anti-IL 23 biologics for the treatment of plaque psoriasis. (Vu A, Ulschmid C, Gordon KB) Expert Opin Biol Ther 2022 Dec;22(12):1489-1502 PMID: 36243011 SCOPUS ID: 2-s2.0-85140999891 10/16/2022 7 Citations

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. (Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, Rich P, Paul C, Bagel J, Colston E, Throup J, Kundu S, Sekaran C, Linaberry M, Banerjee S, Papp KA) J Am Acad Dermatol 2023 Jan;88(1):40-51 PMID: 36115523 SCOPUS ID: 2-s2.0-85144040320 09/18/2022 87 Citations

Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance. (Reich K, Gordon KB, Strober B, Langley RG, Miller M, Yang YW, Shen YK, You Y, Zhu Y, Foley P, Blauvelt A) J Eur Acad Dermatol Venereol 2022 Dec;36(12):2393-2400 PMID: 35920762 SCOPUS ID: 2-s2.0-85136531215 08/04/2022 11 Citations

Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials. (Gordon KB, Langley RG, Warren RB, Okubo Y, Stein Gold L, Merola JF, Peterson L, Wixted K, Cross N, Deherder D, Thaçi D) JAMA Dermatol 2022 Jul 01;158(7):735-744 PMID: 35544084 PMCID: PMC9096693 SCOPUS ID: 2-s2.0-85130365798 05/12/2022 25 Citations

Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study (Crowley JJ, Langley RG, Gordon KB, Pinter A, Ferris LK, Rubant S, Photowala H, Xue Z, Wu T, Zhan T, Beeck S, Shah M, Warren RB) Dermatology and Therapy February 2022;12(2):561-575 SCOPUS ID: 2-s2.0-85123243722 02/01/2022 7 Citations

Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial (Thaçi D, Strober B, Gordon KB, Foley P, Gooderham M, Morita A, Papp KA, Puig L, Menter MA, Colombo MJ, Elbez Y, Kisa RM, Ye J, Napoli AA, Wei L, Banerjee S, Merola JF, Gottlieb AB) Dermatology and Therapy February 2022;12(2):495-510 SCOPUS ID: 2-s2.0-85123098014 02/01/2022 25 Citations

Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study. (Crowley JJ, Langley RG, Gordon KB, Pinter A, Ferris LK, Rubant S, Photowala H, Xue Z, Wu T, Zhan T, Beeck S, Shah M, Warren RB) Dermatol Ther (Heidelb) 2022 Feb;12(2):561-575 PMID: 35050485 PMCID: PMC8850502 SCOPUS ID: 2-s2.0-85123243722 01/21/2022 7 Citations

Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. (Thaçi D, Strober B, Gordon KB, Foley P, Gooderham M, Morita A, Papp KA, Puig L, Menter MA, Colombo MJ, Elbez Y, Kisa RM, Ye J, Napoli AA, Wei L, Banerjee S, Merola JF, Gottlieb AB) Dermatol Ther (Heidelb) 2022 Feb;12(2):495-510 PMID: 35025062 PMCID: PMC8850503 SCOPUS ID: 2-s2.0-85123098014 01/14/2022 25 Citations

Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis (Blauvelt A, Gordon KB, Lee P, Bagel J, Sofen H, Lockshin B, Soliman AM, Geng Z, Zhan T, Alperovich G, Stein Gold L) Journal of Dermatological Treatment 2022;33(4):2085-2093 SCOPUS ID: 2-s2.0-85105382915 01/01/2022 7 Citations

Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis. (Catlett IM, Hu Y, Gao L, Banerjee S, Gordon K, Krueger JG) J Allergy Clin Immunol 2022 Jun;149(6):2010-2020.e8 PMID: 34767869 SCOPUS ID: 2-s2.0-85121371307 11/13/2021 34 Citations

Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. (Gordon KB, Lebwohl M, Papp KA, Bachelez H, Wu JJ, Langley RG, Blauvelt A, Kaplan B, Shah M, Zhao Y, Sinvhal R, Reich K) Br J Dermatol 2022 Mar;186(3):466-475 PMID: 34652810 PMCID: PMC9298814 SCOPUS ID: 2-s2.0-85119997467 10/16/2021 44 Citations

Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. (Reich K, Gordon KB, Strober BE, Armstrong AW, Miller M, Shen YK, You Y, Han C, Yang YW, Foley P, Griffiths CEM) Br J Dermatol 2021 Dec;185(6):1146-1159 PMID: 34105767 SCOPUS ID: 2-s2.0-85114484669 06/10/2021 40 Citations

Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis. (Blauvelt A, Gordon KB, Lee P, Bagel J, Sofen H, Lockshin B, Soliman AM, Geng Z, Zhan T, Alperovich G, Stein Gold L) J Dermatolog Treat 2022 Jun;33(4):2085-2093 PMID: 33947295 SCOPUS ID: 2-s2.0-85105382915 05/06/2021 7 Citations

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. (Reich K, Papp KA, Blauvelt A, Langley RG, Armstrong A, Warren RB, Gordon KB, Merola JF, Okubo Y, Madden C, Wang M, Cioffi C, Vanvoorden V, Lebwohl M) Lancet 2021 Feb 06;397(10273):487-498 PMID: 33549193 SCOPUS ID: 2-s2.0-85100417985 02/08/2021 138 Citations

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. (Gordon KB, Foley P, Krueger JG, Pinter A, Reich K, Vender R, Vanvoorden V, Madden C, White K, Cioffi C, Blauvelt A) Lancet 2021 Feb 06;397(10273):475-486 PMID: 33549192 SCOPUS ID: 2-s2.0-85100381587 02/08/2021 130 Citations

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial (Gordon KB, Foley P, Krueger JG, Pinter A, Reich K, Vender R, Vanvoorden V, Madden C, White K, Cioffi C, Blauvelt A) The Lancet 6 February 2021;397(10273):475-486 SCOPUS ID: 2-s2.0-85100381587 02/06/2021 131 Citations

Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials. (Augustin M, Lambert J, Zema C, Thompson EHZ, Yang M, Wu EQ, Garcia-Horton V, Geng Z, Valdes JM, Joshi A, Gordon KB) JAMA Dermatol 2020 Dec 01;156(12):1344-1353 PMID: 33052382 PMCID: PMC7557488 SCOPUS ID: 2-s2.0-85094184750 10/15/2020 28 Citations

Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study. (Reich K, Armstrong AW, Foley P, Song M, Miller M, Shen YK, You Y, Han C, Gordon KB) Am J Clin Dermatol 2020 Dec;21(6):881-890 PMID: 32910434 SCOPUS ID: 2-s2.0-85090788734 09/11/2020 25 Citations

Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. (Elmets CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Siegel M, Stoff B, Strober B, Wu JJ, Hariharan V, Menter A) J Am Acad Dermatol 2021 Feb;84(2):432-470 PMID: 32738429 SCOPUS ID: 2-s2.0-85092746986 08/02/2020 143 Citations

Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2). (Gordon KB, Warren RB, Gottlieb AB, Blauvelt A, Thaçi D, Leonardi C, Poulin Y, Boehnlein M, Brock F, Ecoffet C, Reich K) Br J Dermatol 2021 Apr;184(4):652-662 PMID: 32652544 PMCID: PMC8247431 SCOPUS ID: 2-s2.0-85090447727 07/12/2020 16 Citations

Cutaneous Manifestations of Chronic Liver Disease. (Patel AD, Katz K, Gordon KB) Clin Liver Dis 2020 Aug;24(3):351-360 PMID: 32620276 SCOPUS ID: 2-s2.0-85085606303 07/06/2020 3 Citations

Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies. (Strober B, Menter A, Leonardi C, Gordon K, Lambert J, Puig L, Photowala H, Longcore M, Zhan T, Foley P) J Eur Acad Dermatol Venereol 2020 Dec;34(12):2830-2838 PMID: 32320088 PMCID: PMC7818271 SCOPUS ID: 2-s2.0-85087425049 04/23/2020 47 Citations

Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. (Menter A, Gelfand JM, Connor C, Armstrong AW, Cordoro KM, Davis DMR, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Prater EF, Rahimi RS, Rupani RN, Siegel M, Stoff B, Strober BE, Tapper EB, Wong EB, Wu JJ, Hariharan V, Elmets CA) J Am Acad Dermatol 2020 Jun;82(6):1445-1486 PMID: 32119894 SCOPUS ID: 2-s2.0-85083507157 03/03/2020 185 Citations

Comparative Effectiveness Studies for Psoriasis-The Methods Matter. (Strober B, Gordon KB) JAMA Dermatol 2020 Mar 01;156(3):253-255 PMID: 32022830 SCOPUS ID: 2-s2.0-85079151739 02/06/2020 1 Citation

Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry. (Callis Duffin K, Mason MA, Gordon K, Harrison RW, Crabtree MM, Guana A, Germino R, Lebwohl M) Dermatology 2021;237(1):46-55 PMID: 31962340 PMCID: PMC7845438 SCOPUS ID: 2-s2.0-85078402956 01/22/2020 20 Citations

Tumor Necrosis Factor Inhibitors (Majerowski J, Gordon KB) Comprehensive Dermatologic Drug Therapy, Fourth Edition 1 January 2020:287-301.e7 SCOPUS ID: 2-s2.0-85143694702 01/01/2020 1 Citation

A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. (Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, Gordon KB, Ferris LK, Langley RG, Tada Y, Lima RG, Elmaraghy H, Gallo G, Renda L, Park SY, Burge R, Bagel J, IXORA-R Study Group) Br J Dermatol 2020 Jun;182(6):1348-1358 PMID: 31887225 PMCID: PMC7317420 SCOPUS ID: 2-s2.0-85078277463 12/31/2019 95 Citations

Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. (Reich K, Griffiths CEM, Gordon KB, Papp KA, Song M, Randazzo B, Li S, Shen YK, Han C, Kimball AB, Armstrong AW, Foley P, Blauvelt A) J Am Acad Dermatol 2020 Apr;82(4):936-945 PMID: 31809827 SCOPUS ID: 2-s2.0-85078983517 12/07/2019 69 Citations

Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis. (Burmester GR, Gordon KB, Rosenbaum JT, Arikan D, Lau WL, Li P, Faccin F, Panaccione R) Adv Ther 2020 Jan;37(1):364-380 PMID: 31748904 PMCID: PMC6979455 SCOPUS ID: 2-s2.0-85075361203 11/22/2019 52 Citations

Defining drug-free remission of skin disease in patients with plaque psoriasis. (Armstrong AW, Blauvelt A, Crowley JJ, Gordon KB, Krueger GG, Krueger JG, Sobell JM, Strober BE, Srivastava B, Menter A) Br J Dermatol 2020 Jun;182(6):1484-1487 PMID: 31705649 SCOPUS ID: 2-s2.0-85078792863 11/11/2019 2 Citations

Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. (Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW, Connor C, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Parra SL, Pathy AL, Farley Prater EA, Rupani RN, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Elmets CA) J Am Acad Dermatol 2020 Jan;82(1):161-201 PMID: 31703821 SCOPUS ID: 2-s2.0-85076301195 11/11/2019 122 Citations

Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. (Langley RGB, Reich K, Strand V, Feldman SR, Paul C, Gordon K, Warren RB, Toth D, Nikaï E, Zhu B, Goldblum O, Edson-Heredia E, Carlier H, Burge R, Lin CY, Hollister K, Augustin M) Qual Life Res 2020 Feb;29(2):369-380 PMID: 31655974 SCOPUS ID: 2-s2.0-85074468701 10/28/2019 4 Citations

Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2. (Reich K, Song M, Li S, Jiang J, Youn SW, Tsai TF, Choe YB, Huang YH, Gordon KB) J Dermatol 2019 Dec;46(12):1141-1152 PMID: 31631377 SCOPUS ID: 2-s2.0-85074357014 10/22/2019 11 Citations

Risankizumab in moderate-to-severe plaque psoriasis. (Serrano L, Maloney V, Gordon KB) Immunotherapy 2019 Nov;11(16):1357-1370 PMID: 31578912 SCOPUS ID: 2-s2.0-85074306957 10/04/2019 4 Citations

Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study. (Lebwohl MG, Gordon KB, Gallo G, Zhang L, Paul C) J Eur Acad Dermatol Venereol 2020 Feb;34(2):301-309 PMID: 31479549 PMCID: PMC7028252 SCOPUS ID: 2-s2.0-85074356669 09/04/2019 24 Citations

Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. (Elmets CA, Lim HW, Stoff B, Connor C, Cordoro KM, Lebwohl M, Armstrong AW, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Kroshinsky D, Leonardi CL, Lichten J, Mehta NN, Paller AS, Parra SL, Pathy AL, Farley Prater EA, Rupani RN, Siegel M, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A) J Am Acad Dermatol 2019 Sep;81(3):775-804 PMID: 31351884 SCOPUS ID: 2-s2.0-85070610651 07/29/2019 102 Citations

Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis. (Elewski B, Menter A, Crowley J, Tyring S, Zhao Y, Lowry S, Rozzo S, Mendelsohn AM, Parno J, Gordon K) J Dermatolog Treat 2020 Dec;31(8):763-768 PMID: 31268369 SCOPUS ID: 2-s2.0-85092347466 07/04/2019 8 Citations

Correlation of Physician-Assessed Psoriasis Area and Severity Index Scores With Patient-Reported Psoriasis Symptoms and Signs Diary Scores Among Patients With Moderate-to-Severe Psoriasis: Results From VOYAGE 1 and VOYAGE 2 Studies (Gordon KB, Han C, Li S, You Y, Song M, Fakharzadeh S, Crowley JJ, Reich K) Journal of Psoriasis and Psoriatic Arthritis 1 July 2019;4(3):147-152 SCOPUS ID: 2-s2.0-85077771098 07/01/2019 3 Citations

Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study. (Gordon KB, Armstrong AW, Foley P, Song M, Shen YK, Li S, Muñoz-Elías EJ, Branigan P, Liu X, Reich K) J Invest Dermatol 2019 Dec;139(12):2437-2446.e1 PMID: 31207232 SCOPUS ID: 2-s2.0-85070241747 06/18/2019 63 Citations

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. (Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA) J Am Acad Dermatol 2019 Apr;80(4):1029-1072 PMID: 30772098 SCOPUS ID: 2-s2.0-85062716482 02/18/2019 565 Citations

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. (Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, Armstrong AW, Connor C, Cordoro KM, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kivelevitch D, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Lim HW, Paller AS, Parra SL, Pathy AL, Prater EF, Rupani R, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A) J Am Acad Dermatol 2019 Apr;80(4):1073-1113 PMID: 30772097 SCOPUS ID: 2-s2.0-85062723724 02/18/2019 285 Citations

IL-23 inhibitors for moderate-to-severe psoriasis. (Ibler E, Gordon KB) Semin Cutan Med Surg 2018 Sep;37(3):158-162 PMID: 30215632 SCOPUS ID: 2-s2.0-85058022054 09/15/2018 13 Citations

Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. (Papp K, Gordon K, Thaçi D, Morita A, Gooderham M, Foley P, Girgis IG, Kundu S, Banerjee S) N Engl J Med 2018 Oct 04;379(14):1313-1321 PMID: 30205746 SCOPUS ID: 2-s2.0-85054421910 09/13/2018 267 Citations

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. (Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H) Lancet 2018 Aug 25;392(10148):650-661 PMID: 30097359 SCOPUS ID: 2-s2.0-85052121985 08/12/2018 430 Citations

Systematic review of the real-world evidence of adalimumab safety in psoriasis registries. (Strober B, Crowley J, Langley RG, Gordon K, Menter A, Leonardi C, Arikan D, Valdecantos WC) J Eur Acad Dermatol Venereol 2018 Dec;32(12):2126-2133 PMID: 30067882 SCOPUS ID: 2-s2.0-85052793737 08/02/2018 13 Citations

Highlights of Skin Disease Education Foundations 42nd Annual Hawaii Dermatology Seminar. (Baldwin HE, Stein Gold LF, Gordon KB, Green JB, Leonardi CL, Sengelmann RD) Semin Cutan Med Surg 2018 Jun;37(4S):S75-S84 PMID: 30016379 07/18/2018

Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials. (Foley P, Gordon K, Griffiths CEM, Wasfi Y, Randazzo B, Song M, Li S, Shen YK, Blauvelt A) JAMA Dermatol 2018 Jun 01;154(6):676-683 PMID: 29799960 PMCID: PMC6145649 SCOPUS ID: 2-s2.0-85048666491 05/26/2018 83 Citations

Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). (Kimball AB, Augustin M, Gordon KB, Krueger GG, Pariser D, Fakharzadeh S, Goyal K, Calabro S, Lee S, Lin R, Li N, Srivastava B, Guenther L) Br J Dermatol 2018 Oct;179(4):984-986 PMID: 29747219 SCOPUS ID: 2-s2.0-85050608246 05/11/2018 11 Citations

Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. (Gordon KB, Armstrong AW, Han C, Foley P, Song M, Wasfi Y, You Y, Shen YK, Reich K) J Eur Acad Dermatol Venereol 2018 Nov;32(11):1940-1949 PMID: 29706008 SCOPUS ID: 2-s2.0-85050508740 05/01/2018 60 Citations

Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis. (Zachariae C, Gordon K, Kimball AB, Lebwohl M, Blauvelt A, Leonardi C, Braun D, McKean-Matthews M, Burge R, Cameron G) J Am Acad Dermatol 2018 Aug;79(2):294-301.e6 PMID: 29653208 SCOPUS ID: 2-s2.0-85048713040 04/14/2018 24 Citations

Practical Strategies for Optimizing Management of Psoriasis. (Wu JJ, Armstrong AW, Gordon KB, Menter MA) Semin Cutan Med Surg 2018 Feb;37(2S):S52-S55 PMID: 29614139 04/04/2018

Common and Not-So-Common Comorbidities of Psoriasis. (Menter MA, Armstrong AW, Gordon KB, Wu JJ) Semin Cutan Med Surg 2018 Feb;37(2S):S48-S51 PMID: 29614138 04/04/2018

Treating to Target-A Realistic Goal in Psoriasis? (Gordon KB, Armstrong AW, Menter MA, Wu JJ) Semin Cutan Med Surg 2018 Feb;37(2S):S44-S47 PMID: 29614137 04/04/2018

The Evolving Landscape of Psoriasis Treatment. (Armstrong AW, Gordon KB, Menter MA, Wu JJ) Semin Cutan Med Surg 2018 Feb;37(2S):S39-S43 PMID: 29614136 04/04/2018

Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis. (Gniadecki R, Leonardi CL, Gordon KB, Gu Y, Geng Z, Nader A, Teixeira HD) J Eur Acad Dermatol Venereol 2018 Aug;32(8):1297-1304 PMID: 29524255 SCOPUS ID: 2-s2.0-85050316751 03/11/2018 9 Citations

Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials. (Gottlieb AB, Gordon K, Hsu S, Elewski B, Eichenfield LF, Kircik L, Rastogi S, Pillai R, Israel R) J Eur Acad Dermatol Venereol 2018 Aug;32(8):1305-1313 PMID: 29512200 SCOPUS ID: 2-s2.0-85044522022 03/08/2018 28 Citations

Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. (Papp KA, Gordon KB, Langley RG, Lebwohl MG, Gottlieb AB, Rastogi S, Pillai R, Israel RJ) Br J Dermatol 2018 Aug;179(2):320-328 PMID: 29488226 SCOPUS ID: 2-s2.0-85052198325 03/01/2018 58 Citations

Common and Not-So-Common Comorbidities of Psoriasis (Alan Menter M, Armstrong AW, Gordon KB, Wu JJ) Seminars in Cutaneous Medicine and Surgery March 2018;37(2 S):S49-S52 SCOPUS ID: 2-s2.0-85100300023 03/01/2018 23 Citations

Treating to target-a realistic goal in psoriasis? (Gordon KB, Armstrong AW, Alan Menter M, Wu JJ) Seminars in Cutaneous Medicine and Surgery March 2018;37(2 S):S45-S48 SCOPUS ID: 2-s2.0-85065929766 03/01/2018 9 Citations

Practical Strategies for Optimizing Management of Psoriasis (Wu JJ, Armstrong AW, Gordon KB, Alan Menter M) Seminars in Cutaneous Medicine and Surgery March 2018;37(2 S):S53-S56 SCOPUS ID: 2-s2.0-85058867566 03/01/2018 3 Citations

The evolving landscape of psoriasis treatment (Armstrong AW, Gordon KB, Alan Menter M, Wu JJ) Seminars in Cutaneous Medicine and Surgery March 2018;37(2 S):S40-S44 SCOPUS ID: 2-s2.0-85058867514 03/01/2018 8 Citations

Immunogenicity of biologic agents in psoriasis (Florek AG, Gordon KB) Biologic and Systemic Agents in Dermatology 2 January 2018:93-99 SCOPUS ID: 2-s2.0-85046150510 01/02/2018

Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials. (Gordon KB, Betts KA, Sundaram M, Signorovitch JE, Li J, Xie M, Wu EQ, Okun MM) J Am Acad Dermatol 2017 Dec;77(6):1030-1037 PMID: 28993007 SCOPUS ID: 2-s2.0-85030755527 10/11/2017 7 Citations

Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis. (Viswanathan HN, Mutebi A, Milmont CE, Gordon K, Wilson H, Zhang H, Klekotka PA, Revicki DA, Augustin M, Kricorian G, Nirula A, Strober B) Value Health 2017 Sep;20(8):1174-1179 PMID: 28964451 SCOPUS ID: 2-s2.0-85020489769 10/02/2017 9 Citations

Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. (Gordon KB, Blauvelt A, Foley P, Song M, Wasfi Y, Randazzo B, Shen YK, You Y, Griffiths CEM) Br J Dermatol 2018 Jan;178(1):132-139 PMID: 28940259 SCOPUS ID: 2-s2.0-85037985932 09/25/2017 61 Citations

Highlights of Skin Disease Education Foundation's 41st Annual Hawaii Dermatology Seminar™. (Gordon KB, Leonardi CL, Furst DE, Bhatia N, Eichenfield LF, Beleznay K) Semin Cutan Med Surg 2017 Jun;36(4S):S52-S59 PMID: 28745729 07/27/2017

Highlights of Skin Disease Education Foundation's 41st Annual Hawaii Dermatology Seminar^TM (Gordon KB, Leonardi CL, Furst DE, Bhatia N, Eichenfield LF, Beleznay K) Seminars in Cutaneous Medicine and Surgery June 2017;36(3S):S52-S58 SCOPUS ID: 2-s2.0-85118883037 06/01/2017

Biologic therapies for psoriasis (Guggina L, Gordon KB) Clinical and Basic Immunodermatology: Second Edition 24 April 2017:757-765 SCOPUS ID: 2-s2.0-85035351769 04/24/2017

Association of psoriasis and psoriatic arthritis with osteoporosis and pathological fractures. (Kathuria P, Gordon KB, Silverberg JI) J Am Acad Dermatol 2017 Jun;76(6):1045-1053.e3 PMID: 28314685 SCOPUS ID: 2-s2.0-85019482841 03/21/2017 47 Citations

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis. (Blauvelt A, Papp KA, Sofen H, Augustin M, Yosipovitch G, Katoh N, Mrowietz U, Ohtsuki M, Poulin Y, Shrom D, Burge R, See K, Mallbris L, Gordon KB) J Eur Acad Dermatol Venereol 2017 Jun;31(6):1004-1013 PMID: 28190255 PMCID: PMC5485049 SCOPUS ID: 2-s2.0-85017400588 02/13/2017 53 Citations

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. (Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB) J Am Acad Dermatol 2017 Mar;76(3):418-431 PMID: 28057361 SCOPUS ID: 2-s2.0-85008601511 01/07/2017 535 Citations

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. (Gordon KB, Colombel JF, Hardin DS) N Engl J Med 2016 Nov 24;375(21):2102 PMID: 27959738 SCOPUS ID: 2-s2.0-84997794642 12/14/2016 23 Citations

Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis. (Tan H, Valdez H, Griffins CE, Mrowietz U, Tallman A, Wolk R, Gordon K) J Dermatolog Treat 2017 Feb;28(1):3-7 PMID: 27538247 SCOPUS ID: 2-s2.0-84982252380 08/19/2016 8 Citations

Translating the Science of Psoriasis. (Gordon KB) Semin Cutan Med Surg 2016 Jun;35(4 Suppl 4):S64 PMID: 27526392 SCOPUS ID: 2-s2.0-84988485517 08/16/2016 3 Citations

Serious infections in hospitalized patients with psoriasis in the United States. (Hsu DY, Gordon K, Silverberg JI) J Am Acad Dermatol 2016 Aug;75(2):287-96 PMID: 27324314 SCOPUS ID: 2-s2.0-84992027539 06/22/2016 40 Citations

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. (Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL, UNCOVER-1 Study Group, UNCOVER-2 Study Group, UNCOVER-3 Study Group) N Engl J Med 2016 Jul 28;375(4):345-56 PMID: 27299809 SCOPUS ID: 2-s2.0-84977071601 06/15/2016 635 Citations

The inpatient burden of psoriasis in the United States. (Hsu DY, Gordon K, Silverberg JI) J Am Acad Dermatol 2016 Jul;75(1):33-41 PMID: 27210045 SCOPUS ID: 2-s2.0-84969504528 05/24/2016 23 Citations

Clinical meaningfulness of complete skin clearance in psoriasis. (Strober B, Papp KA, Lebwohl M, Reich K, Paul C, Blauvelt A, Gordon KB, Milmont CE, Viswanathan HN, Li J, Pinto L, Harrison DJ, Kricorian G, Nirula A, Klekotka P) J Am Acad Dermatol 2016 Jul;75(1):77-82.e7 PMID: 27206759 SCOPUS ID: 2-s2.0-84971333765 05/22/2016 93 Citations

Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials. (Armstrong AW, Lynde CW, McBride SR, Ståhle M, Edson-Heredia E, Zhu B, Amato D, Nikaï E, Yang FE, Gordon KB) JAMA Dermatol 2016 Jun 01;152(6):661-9 PMID: 26953848 SCOPUS ID: 2-s2.0-84975132508 03/10/2016 46 Citations

Diagnosis and evaluation of psoriasis and psoriatic arthritis (Ruderman E, Gordon KB) Handbook of Psoriasis and Psoriatic Arthritis 1 January 2016:27-42 SCOPUS ID: 2-s2.0-84960304083 01/01/2016

Update on New and Emerging Therapies in the Management of Psoriasis. (Gordon KB Md) Semin Cutan Med Surg 2015 Mar;34(2 Suppl):S34-6 PMID: 26623549 12/02/2015

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. (Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, Papp K, Spelman L, Toth D, Kerdel F, Armstrong AW, Stingl G, Kimball AB, Bachelez H, Wu JJ, Crowley J, Langley RG, Blicharski T, Paul C, Lacour JP, Tyring S, Kircik L, Chimenti S, Callis Duffin K, Bagel J, Koo J, Aras G, Li J, Song W, Milmont CE, Shi Y, Erondu N, Klekotka P, Kotzin B, Nirula A) N Engl J Med 2015 Oct;373(14):1318-28 PMID: 26422722 SCOPUS ID: 2-s2.0-84942876148 10/01/2015 657 Citations

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. (Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, Shen YK, Szapary P, Randazzo B, Reich K) N Engl J Med 2015 Jul 09;373(2):136-44 PMID: 26154787 SCOPUS ID: 2-s2.0-84936763292 07/15/2015 262 Citations

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). (Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, Hu C, Stevens RM, Day RM, Gordon KB, Korman NJ, Griffiths CE) J Am Acad Dermatol 2015 Jul;73(1):37-49 PMID: 26089047 SCOPUS ID: 2-s2.0-84937880965 06/20/2015 471 Citations

A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab. (Edson-Heredia E, Banerjee S, Zhu B, Maeda-Chubachi T, Cameron GS, Shen W, Heffernan MP, Gordon KB, Leonardi CL) J Eur Acad Dermatol Venereol 2016 May;30(5):864-5 PMID: 25773781 SCOPUS ID: 2-s2.0-84924678707 03/17/2015 27 Citations

Patient satisfaction and quality of life in psoriasis and psoriatic arthritis. (Mercy KM, Gordon KB, Paller AS) JAMA 2014 Dec 24-31;312(24):2676-7 PMID: 25536259 SCOPUS ID: 2-s2.0-84920025618 12/24/2014 8 Citations

Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption. (Gordon KB, Gottlieb AB, Langely RG, van de Kerkhof P, Belasco KT, Sundaram M, Okun M, Serra L) J Eur Acad Dermatol Venereol 2015 Apr;29(4):767-76 PMID: 25284275 SCOPUS ID: 2-s2.0-84925395935 10/07/2014 17 Citations

A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. (Gordon KB, Leonardi CL, Lebwohl M, Blauvelt A, Cameron GS, Braun D, Erickson J, Heffernan M) J Am Acad Dermatol 2014 Dec;71(6):1176-82 PMID: 25242558 SCOPUS ID: 2-s2.0-84919783193 09/23/2014 94 Citations

Unmet needs in the treatment of psoriasis. (Kragballe K, van de Kerkhof PC, Gordon KB) Eur J Dermatol 2014;24(5):523-32 PMID: 25115238 SCOPUS ID: 2-s2.0-84919394318 08/15/2014 20 Citations

New and emerging therapies in psoriasis. (Leonardi CL, Gordon KB) Semin Cutan Med Surg 2014 Mar;33(2 Suppl 2):S37-41 PMID: 24979544 SCOPUS ID: 2-s2.0-84905588626 07/01/2014 22 Citations

Understanding therapeutic pathways and comorbidities in psoriasis. (Gordon KB, Strober BE) Semin Cutan Med Surg 2014 Mar;33(2 Suppl 2):S20-3 PMID: 24979540 SCOPUS ID: 2-s2.0-84905587939 07/01/2014 4 Citations

Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2013 MauiDerm Meeting. (Blauvelt A, Brown M, Gordon KB, Kavanaugh A, Leonardi CT, Stockfleth E, Strober B, Swanson NA, Martin G) J Clin Aesthet Dermatol 2013 Sep;6(9 Suppl):S2-S20 PMID: 24167640 PMCID: PMC3809592 10/30/2013

Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory. (Gordon KB, Kimball AB, Chau D, Viswanathan HN, Li J, Revicki DA, Kricorian G, Ortmeier BG) Br J Dermatol 2014 Mar;170(3):705-15 PMID: 24079852 PMCID: PMC4153951 SCOPUS ID: 2-s2.0-84896088319 10/02/2013 43 Citations

Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis. (Zhu B, Edson-Heredia E, Cameron GS, Shen W, Erickson J, Shrom D, Wang P, Banerjee S, Gordon KB) Br J Dermatol 2013 Dec;169(6):1337-41 PMID: 24032554 SCOPUS ID: 2-s2.0-84887968942 09/17/2013 35 Citations

Rationale and early clinical data on IL-17 blockade in psoriasis. (Nwe SM, Champlain AH, Gordon KB) Expert Rev Clin Immunol 2013 Jul;9(7):677-82 PMID: 23899238 SCOPUS ID: 2-s2.0-84883233394 08/01/2013 13 Citations

Systemics to topicals in psoriasis: the unfilled need. (Lingam P, Nwe S, Gordon KB) Br J Dermatol 2013 Jul;169(1):2-3 PMID: 23834112 SCOPUS ID: 2-s2.0-84879900454 07/10/2013

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. (Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, Chan D, Hsu MC, Ho V, Ghislain PD, Strober B, Reich K, PHOENIX 1 Investigators, PHOENIX 2 Investigators, ACCEPT Investigators) Br J Dermatol 2013 Apr;168(4):844-54 PMID: 23301632 SCOPUS ID: 2-s2.0-84875433817 01/11/2013 352 Citations

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. (Kimball AB, Papp KA, Wasfi Y, Chan D, Bissonnette R, Sofen H, Yeilding N, Li S, Szapary P, Gordon KB, PHOENIX 1 Investigators) J Eur Acad Dermatol Venereol 2013 Dec;27(12):1535-45 PMID: 23279003 SCOPUS ID: 2-s2.0-84888205088 01/03/2013 181 Citations

Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity. (Martin ML, McCarrier KP, Chiou CF, Gordon K, Kimball AB, Van Voorhees AS, Gottlieb AB, Huang X, Globe D, Chau D, Viswanathan HN, Kricorian G) J Dermatolog Treat 2013 Aug;24(4):255-60 PMID: 23249143 SCOPUS ID: 2-s2.0-84880214727 12/20/2012 32 Citations

A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2. (Strober BE, Clay Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb AB, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Schwartzman S, Sobell JM, Solomon GE, Young M) Dermatol Ther (Heidelb) 2012 Dec;2(1):2 PMID: 23205325 PMCID: PMC3510406 12/04/2012

A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1. (Strober BE, Clay Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb AB, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Schwartzman S, Sobell JM, Solomon GE, Young M) Dermatol Ther (Heidelb) 2012 Dec;2(1):1 PMID: 23205324 PMCID: PMC3510391 SCOPUS ID: 2-s2.0-84871414250 12/04/2012 2 Citations

Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. (Langley RG, Papp K, Gottlieb AB, Krueger GG, Gordon KB, Williams D, Valdes J, Setze C, Strober B) J Eur Acad Dermatol Venereol 2013 Oct;27(10):1252-61 PMID: 23157612 SCOPUS ID: 2-s2.0-84884900971 11/20/2012 59 Citations

Tumor necrosis factor (TNF) inhibitors (Mehlis S, Gordon KB) Comprehensive Dermatologic Drug Therapy: Expert Consult - Online and Print 16 November 2012:307-318 SCOPUS ID: 2-s2.0-85135418421 11/16/2012

PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. (Papp KA, Strober B, Augustin M, Calabro S, Londhe A, Chevrier M, PSOLAR investigators and Steering Committee) J Drugs Dermatol 2012 Oct;11(10):1210-7 PMID: 23134986 SCOPUS ID: 2-s2.0-84868611859 11/09/2012 80 Citations

Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity. (Bushnell DM, Martin ML, McCarrier K, Gordon K, Chiou CF, Huang X, Ortmeier B, Kricorian G) J Dermatolog Treat 2013 Oct;24(5):356-60 PMID: 23092173 SCOPUS ID: 2-s2.0-84883575731 10/25/2012 53 Citations

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. (Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP) Ann Rheum Dis 2013 Apr;72(4):517-24 PMID: 22562972 PMCID: PMC3595151 SCOPUS ID: 2-s2.0-84874445437 05/09/2012 460 Citations

An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. (Reich K, Papp KA, Griffiths CE, Szapary PO, Yeilding N, Wasfi Y, Ott E, Hsu MC, Lebwohl M, Gordon KB, PHOENIX 1, PHOENIX 2, and ACCEPT investigators) J Drugs Dermatol 2012 Mar;11(3):300-12 PMID: 22395580 SCOPUS ID: 2-s2.0-84858633545 03/08/2012 74 Citations

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. (Kimball AB, Gordon KB, Fakharzadeh S, Yeilding N, Szapary PO, Schenkel B, Guzzo C, Li S, Papp KA) Br J Dermatol 2012 Apr;166(4):861-72 PMID: 22356258 SCOPUS ID: 2-s2.0-84859118948 02/24/2012 122 Citations

Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis. (Pariser DM, Leonardi CL, Gordon K, Gottlieb AB, Tyring S, Papp KA, Li J, Baumgartner SW) J Am Acad Dermatol 2012 Aug;67(2):245-56 PMID: 22015149 SCOPUS ID: 2-s2.0-84863984952 10/22/2011 68 Citations

A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. (Gordon KB, Langley RG, Gottlieb AB, Papp KA, Krueger GG, Strober BE, Williams DA, Gu Y, Valdes JM) J Invest Dermatol 2012 Feb;132(2):304-14 PMID: 22011907 SCOPUS ID: 2-s2.0-84855938590 10/21/2011 147 Citations

Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. (Gordon KB, Papp KA, Langley RG, Ho V, Kimball AB, Guzzo C, Yeilding N, Szapary PO, Fakharzadeh S, Li S, Hsu MC, Reich K) J Am Acad Dermatol 2012 May;66(5):742-51 PMID: 21978572 SCOPUS ID: 2-s2.0-84859869815 10/08/2011 121 Citations

Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. (Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB, Langley RG, de Lemos JA, Daoud Y, Blankenship D, Kazi S, Kaplan DH, Friedewald VE, Menter A) JAMA 2011 Aug 24;306(8):864-71 PMID: 21862748 SCOPUS ID: 2-s2.0-80052074383 08/25/2011 259 Citations

Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. (Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH) J Am Acad Dermatol 2012 Feb;66(2):241-51 PMID: 21752491 SCOPUS ID: 2-s2.0-84855849399 07/15/2011 150 Citations

Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. (American Academy of Dermatology Work Group, Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Leonardi CL, Lim HW, Van Voorhees AS, Beutner KR, Ryan C, Bhushan R) J Am Acad Dermatol 2011 Jul;65(1):137-74 PMID: 21306785 SCOPUS ID: 2-s2.0-79958800583 02/11/2011 412 Citations

Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial. (Kimball AB, Gordon KB, Langley RG, Menter A, Perdok RJ, Valdes J, ABT-874 Study Investigators) J Am Acad Dermatol 2011 Feb;64(2):263-74 PMID: 21145618 SCOPUS ID: 2-s2.0-78751580638 12/15/2010 27 Citations

Ustekinumab: An evidence-based review of its effectiveness in the treatment of psoriasis (Krulig E, Gordon KB) Core Evidence 2010;5:11-22 SCOPUS ID: 2-s2.0-79959349662 12/01/2010 17 Citations

Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis. (Krulig E, Gordon KB) Core Evid 2010 Jul 27;5:11-22 PMID: 20694136 PMCID: PMC2915500 08/10/2010

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. (Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM) J Am Acad Dermatol 2010 Sep;63(3):448-56 PMID: 20605254 SCOPUS ID: 2-s2.0-77955924889 07/08/2010 137 Citations

Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. (Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu MC, Ortonne JP, Gordon KB, Kimball AB) J Am Acad Dermatol 2010 Sep;63(3):457-65 PMID: 20462664 SCOPUS ID: 2-s2.0-77955921585 05/14/2010 184 Citations

Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. (Gandhi M, Alwawi E, Gordon KB) Semin Cutan Med Surg 2010 Mar;29(1):48-52 PMID: 20430307 SCOPUS ID: 2-s2.0-77951605086 05/01/2010 56 Citations

Strategies for treatment with anti-tumor necrosis factor agents in psoriasis: maintaining efficacy and safety for the long haul. (Gordon KB, Gandhi M) Arch Dermatol 2010 Feb;146(2):186-8 PMID: 20157030 SCOPUS ID: 2-s2.0-76749162835 02/17/2010 1 Citation

Long-term efficacy of biologics in the treatment of psoriasis: what do we really know? (Alwawi EA, Krulig E, Gordon KB) Dermatol Ther 2009;22(5):431-40 PMID: 19845720 SCOPUS ID: 2-s2.0-69749085182 10/23/2009 38 Citations

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. (Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JYM, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R) J Am Acad Dermatol 2010 Jan;62(1):114-135 PMID: 19811850 SCOPUS ID: 2-s2.0-71649108156 10/09/2009 310 Citations

A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach. (Strober B, Berger E, Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb A, Horn EJ, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Menter A, Schwartzman S, Sobell JM, Young M) J Am Acad Dermatol 2009 Jul;61(1 Suppl 1):S1-S46 PMID: 19527820 SCOPUS ID: 2-s2.0-67649659930 06/19/2009 27 Citations

Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. (Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb AB, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R) J Am Acad Dermatol 2009 Sep;61(3):451-85 PMID: 19493586 SCOPUS ID: 2-s2.0-68949149916 06/06/2009 495 Citations

Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. (Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R, American Academy of Dermatology) J Am Acad Dermatol 2009 Apr;60(4):643-59 PMID: 19217694 SCOPUS ID: 2-s2.0-62049084468 02/17/2009 452 Citations

Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. (Burmester GR, Mease P, Dijkmans BA, Gordon K, Lovell D, Panaccione R, Perez J, Pangan AL) Ann Rheum Dis 2009 Dec;68(12):1863-9 PMID: 19147611 PMCID: PMC2770105 SCOPUS ID: 2-s2.0-67149120677 01/17/2009 180 Citations

AJC editor's consensus: psoriasis and coronary artery disease. (Friedewald VE, Cather JC, Gelfand JM, Gordon KB, Gibbons GH, Grundy SM, Jarratt MT, Krueger JG, Ridker PM, Stone N, Roberts WC) Am J Cardiol 2008 Dec 15;102(12):1631-43 PMID: 19064017 SCOPUS ID: 2-s2.0-58149477214 12/10/2008 149 Citations

Treating psoriasis with adalimumab. (Alwawi EA, Mehlis SL, Gordon KB) Ther Clin Risk Manag 2008 Apr;4(2):345-51 PMID: 18728850 PMCID: PMC2504074 08/30/2008

Rethinking eligibility creep. (Kazanis M, Leonardi C, Gordon K, Strober B, Menter A, Kimball AB) J Am Acad Dermatol 2008 Jul;59(1):165-7; author reply 167 PMID: 18571602 SCOPUS ID: 2-s2.0-45149134742 06/24/2008 1 Citation

Treating psoriasis with adalimumab (Alwawi EA, Mehlis SL, Gordon KB) Therapeutics and Clinical Risk Management 2008;4(2):345-351 SCOPUS ID: 2-s2.0-44049090388 05/27/2008 37 Citations

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). (Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K, PHOENIX 2 study investigators) Lancet 2008 May 17;371(9625):1675-84 PMID: 18486740 SCOPUS ID: 2-s2.0-43449139402 05/20/2008 1313 Citations

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). (Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB, PHOENIX 1 study investigators) Lancet 2008 May 17;371(9625):1665-74 PMID: 18486739 SCOPUS ID: 2-s2.0-43449111187 05/20/2008 1474 Citations

Therapeutics and immune-mediated skin disease. (Gordon KB, Satoskar R) Curr Dir Autoimmun 2008;10:359-72 PMID: 18460896 SCOPUS ID: 2-s2.0-49049114617 05/08/2008

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. (Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, Van Voorhees AS, Elmets CA, Leonardi CL, Beutner KR, Bhushan R, Menter A) J Am Acad Dermatol 2008 May;58(5):851-64 PMID: 18423261 SCOPUS ID: 2-s2.0-41949096736 04/22/2008 384 Citations

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. (Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R) J Am Acad Dermatol 2008 May;58(5):826-50 PMID: 18423260 SCOPUS ID: 2-s2.0-41949094481 04/22/2008 1162 Citations

The editor's roundtable: psoriasis, inflammation, and coronary artery disease. (Friedewald VE Jr, Cather JC, Gordon KB, Kavanaugh A, Ridker PM, Roberts WC) Am J Cardiol 2008 Apr 15;101(8):1119-26 PMID: 18394444 SCOPUS ID: 2-s2.0-41549148225 04/09/2008 26 Citations

National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. (Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, Korver G, Krueger GG, Strober BE, Lebwohl MG, National Psoriasis Foundation) J Am Acad Dermatol 2008 Jun;58(6):1031-42 PMID: 18313171 PMCID: PMC3716382 SCOPUS ID: 2-s2.0-43449137849 03/04/2008 384 Citations

Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. (Kimball AB, Gordon KB, Langley RG, Menter A, Chartash EK, Valdes J, ABT-874 Psoriasis Study Investigators) Arch Dermatol 2008 Feb;144(2):200-7 PMID: 18283176 SCOPUS ID: 2-s2.0-39649108216 02/20/2008 214 Citations

Duration of remission of biologic agents for chronic plaque psoriasis. (Langley RG, Gordon KB) J Drugs Dermatol 2007 Dec;6(12):1205-12 PMID: 18189060 SCOPUS ID: 2-s2.0-38849191950 01/15/2008 18 Citations

Palmoplantar psoriasis (Krulig E, Gordon KB) Mild-to-Moderate Psoriasis, Second Edition 1 January 2008:183-195 SCOPUS ID: 2-s2.0-85123152336 01/01/2008 1 Citation

Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. (Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, Langley RG, Kimel M, Okun M) J Dermatolog Treat 2007;18(6):341-50 PMID: 18058494 SCOPUS ID: 2-s2.0-36849070806 12/07/2007 91 Citations

Biologic Immunotherapy of Psoriasis (Gordon K) Handbook of Psoriasis: Second Edition 30 November 2007:328-337 SCOPUS ID: 2-s2.0-84889343014 11/30/2007

From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. (Lebwohl M, Bagel J, Gelfand JM, Gladman D, Gordon KB, Hsu S, Kalb RE, Kimball AB, Korman NJ, Krueger GG, Mease P, Morison WL, Paller A, Pariser DM, Ritchlin C, Strober B, Van Voorhees A, Weinstein GD, Young M, Horn L) J Am Acad Dermatol 2008 Jan;58(1):94-105 PMID: 17980456 SCOPUS ID: 2-s2.0-37349054996 11/06/2007 100 Citations

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. (Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, Strober BE, Kaul M, Gu Y, Okun M, Papp K) J Am Acad Dermatol 2008 Jan;58(1):106-15 PMID: 17936411 SCOPUS ID: 2-s2.0-37349003068 10/16/2007 792 Citations

Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation. (Marble DJ, Gordon KB, Nickoloff BJ) J Dermatol Sci 2007 Nov;48(2):87-101 PMID: 17689932 PMCID: PMC2703191 SCOPUS ID: 2-s2.0-34548535119 08/11/2007 57 Citations

The new psoriasis pathway: toward a unified theory of immunopathogenesis. (Melhis SL, Gordon KB) Expert Rev Clin Immunol 2007 Jul;3(4):447-50 PMID: 20477148 SCOPUS ID: 2-s2.0-34447637621 07/01/2007 1 Citation

Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. (Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, Jahreis A) Arch Dermatol 2007 Jun;143(6):719-26 PMID: 17576937 SCOPUS ID: 2-s2.0-34250761386 06/20/2007 313 Citations

The first World Psoriasis and Psoriatic Arthritis Conference. (Horn E, Gordon K, Mease P) J Invest Dermatol 2007 Jul;127(7):1566-7 PMID: 17568796 SCOPUS ID: 2-s2.0-34250629626 06/15/2007

Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity. (Toor AA, Stiff PJ, Nickoloff BJ, Rodriguez T, Klein JL, Gordon KB) J Dermatolog Treat 2007;18(1):13-8 PMID: 17365261 SCOPUS ID: 2-s2.0-33947162398 03/17/2007 19 Citations

A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. (Moore A, Gordon KB, Kang S, Gottlieb A, Freundlich B, Xia HA, Stevens SR) J Am Acad Dermatol 2007 Apr;56(4):598-603 PMID: 17113190 SCOPUS ID: 2-s2.0-33947182547 11/23/2006 149 Citations

Lessons learned from psoriatic plaques concerning mechanisms of tissue repair, remodeling, and inflammation. (Nickoloff BJ, Bonish BK, Marble DJ, Schriedel KA, DiPietro LA, Gordon KB, Lingen MW) J Investig Dermatol Symp Proc 2006 Sep;11(1):16-29 PMID: 17069007 SCOPUS ID: 2-s2.0-33748778748 10/31/2006 66 Citations

Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. (Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, Heffernan M, Miller B, Hamlin R, Lim L, Zhong J, Hoffman R, Okun MM) J Am Acad Dermatol 2006 Oct;55(4):598-606 PMID: 17010738 SCOPUS ID: 2-s2.0-33748936662 10/03/2006 473 Citations

Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. (Papp KA, Bressinck R, Fretzin S, Goffe B, Kempers S, Gordon KB, Caro I, Walicke PA, Wang X, Menter A, Efalizumab Study Group) Int J Dermatol 2006 May;45(5):605-14 PMID: 16700803 SCOPUS ID: 2-s2.0-33646167222 05/17/2006 72 Citations

Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I. (Pariser DM, Gordon KB, Papp KA, Leonardi CL, Kwon P, Compton PG, Rundle AC, Walicke PA, Lebwohl M) J Cutan Med Surg 2005 Dec;9(6):303-12 PMID: 16699904 SCOPUS ID: 2-s2.0-33749322774 05/16/2006 30 Citations

Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis. (Papp KA, Miller B, Gordon KB, Caro I, Kwon P, Compton PG, Leonardi CL, Efalizumab Study Group) J Am Acad Dermatol 2006 Apr;54(4 Suppl 1):S164-70 PMID: 16488338 SCOPUS ID: 2-s2.0-32544439509 02/21/2006 39 Citations

The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach. (Gordon KB, Ruderman EM) J Am Acad Dermatol 2006 Mar;54(3 Suppl 2):S85-91 PMID: 16488334 SCOPUS ID: 2-s2.0-32644435765 02/21/2006 34 Citations

Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. (Gordon K, Korman N, Frankel E, Wang H, Jahreis A, Zitnik R, Chang T) J Am Acad Dermatol 2006 Mar;54(3 Suppl 2):S101-11 PMID: 16488320 SCOPUS ID: 2-s2.0-32644441215 02/21/2006 88 Citations

Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. (Gordon KB, Gottlieb AB, Leonardi CL, Elewski BE, Wang A, Jahreis A, Zitnik R) J Dermatolog Treat 2006;17(1):9-17 PMID: 16467018 SCOPUS ID: 2-s2.0-32644479353 02/10/2006 108 Citations

Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. (Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Lalla D, Woolley M, Jahreis A, Zitnik R, Cella D, Krishnan R) Lancet 2006 Jan 07;367(9504):29-35 PMID: 16399150 SCOPUS ID: 2-s2.0-29844440963 01/10/2006 968 Citations

Psoriasis (Gordon KB) Psoriasis and Psoriatic Arthritis: An Integrated Approach 2005:125-128 SCOPUS ID: 2-s2.0-84890010036 12/01/2005 2 Citations

Psoriasis and psoriatic arthritis: An integrated approach (Gordon KB, Ruderman EM) Psoriasis and Psoriatic Arthritis: An Integrated Approach 2005:1-252 SCOPUS ID: 2-s2.0-84889996758 12/01/2005 3 Citations

Introduction (Gordon KB, Ruderman EM) Psoriasis and Psoriatic Arthritis: An Integrated Approach 2005:1-2 SCOPUS ID: 2-s2.0-84889986336 12/01/2005

Preface (Gordon KB, Ruderman EM) Psoriasis and Psoriatic Arthritis: An Integrated Approach 2005 SCOPUS ID: 2-s2.0-84889964005 12/01/2005 1 Citation

Synthesis and conclusion (Gordon KB, Ruderman EM) Psoriasis and Psoriatic Arthritis: An Integrated Approach 2005:245-250 SCOPUS ID: 2-s2.0-32644445026 12/01/2005 2 Citations

Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience. (Langley RG, Carey WP, Rafal ES, Tyring SK, Caro I, Wang X, Wetherill G, Gordon KB) Clin Ther 2005 Sep;27(9):1317-28 PMID: 16291408 SCOPUS ID: 2-s2.0-27744466915 11/18/2005 56 Citations

The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. (Gordon KB, Bonish BK, Patel T, Leonardi CL, Nickoloff BJ) Br J Dermatol 2005 Nov;153(5):945-53 PMID: 16225604 SCOPUS ID: 2-s2.0-27544465904 10/18/2005 59 Citations

Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis. (Quinn AM, Brown K, Bonish BK, Curry J, Gordon KB, Sinacore J, Gamelli R, Nickoloff BJ) Arch Dermatol 2005 Jun;141(6):683-7 PMID: 15967913 SCOPUS ID: 2-s2.0-21844472796 06/22/2005 69 Citations

Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. (Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, Guzzo C, Patel K, Menter A, Gottlieb AB) Br J Dermatol 2005 May;152(5):954-60 PMID: 15888152 SCOPUS ID: 2-s2.0-21044440425 05/13/2005 121 Citations

Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. (Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, Walicke PA, Compton PG, Gottlieb AB, Efalizumab Study Group) J Am Acad Dermatol 2005 Mar;52(3 Pt 1):425-33 PMID: 15761420 SCOPUS ID: 2-s2.0-17144388751 03/12/2005 223 Citations

Psoriasis treatment: current and emerging directed therapies. (Winterfield LS, Menter A, Gordon K, Gottlieb A) Ann Rheum Dis 2005 Mar;64 Suppl 2(Suppl 2):ii87-90; discussion ii91-2 PMID: 15708946 PMCID: PMC1766866 SCOPUS ID: 2-s2.0-14244262057 02/15/2005 105 Citations

The efficacy of alefacept in the treatment of chronic plaque psoriasis. (Gordon KB, Valentine J) J Cutan Med Surg 2004 Dec;8 Suppl 2:3-9 PMID: 15668749 SCOPUS ID: 2-s2.0-13644250766 01/26/2005 4 Citations

Definitions of measures of effect duration for psoriasis treatments. (Gordon KB, Feldman SR, Koo JY, Menter A, Rolstad T, Krueger G) Arch Dermatol 2005 Jan;141(1):82-4 PMID: 15655149 SCOPUS ID: 2-s2.0-12444266783 01/19/2005 53 Citations

Patient education and advocacy groups: a means to better outcomes? (Gordon KB) Arch Dermatol 2005 Jan;141(1):80-1 PMID: 15655148 SCOPUS ID: 2-s2.0-12444318598 01/19/2005 6 Citations

Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. (Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, Li N, Gulliver W) Arch Dermatol 2005 Jan;141(1):31-8 PMID: 15655139 SCOPUS ID: 2-s2.0-12444336904 01/19/2005 215 Citations

Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. (Gottlieb AB, Gordon KB, Lebwohl MG, Caro I, Walicke PA, Li N, Leonardi CL, EFALIZUMAB STUDY GROUP) J Drugs Dermatol 2004;3(6):614-24 PMID: 15624744 SCOPUS ID: 2-s2.0-15744387890 12/31/2004 80 Citations

From laboratory to clinic: rationale for biologic therapy. (Mehlis S, Gordon KB) Dermatol Clin 2004 Oct;22(4):371-7, vii-viii PMID: 15450333 SCOPUS ID: 2-s2.0-4344709636 09/29/2004 15 Citations

Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis. (Patel T, Gordon KB) Dermatol Ther 2004;17(5):427-31 PMID: 15379777 SCOPUS ID: 2-s2.0-6344286067 09/24/2004 65 Citations

Remittive effects of intramuscular alefacept in psoriasis. (Gordon KB, Langley RG) J Drugs Dermatol 2003 Dec;2(6):624-8 PMID: 14711140 SCOPUS ID: 2-s2.0-1342309259 01/09/2004 69 Citations

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. (Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, Bresnahan BW, Menter A, Efalizumab Study Group) JAMA 2003 Dec 17;290(23):3073-80 PMID: 14679270 SCOPUS ID: 2-s2.0-0346515709 12/18/2003 387 Citations

A randomized trial of etanercept as monotherapy for psoriasis. (Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, Gaspari AA, Ling M, Weinstein GD, Nayak A, Gordon KB, Zitnik R) Arch Dermatol 2003 Dec;139(12):1627-32; discussion 1632 PMID: 14676082 SCOPUS ID: 2-s2.0-10744221697 12/17/2003 455 Citations

Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts. (Gordon KB, Vaishnaw AK, O'Gorman J, Haney J, Menter A, Alefacept Clinical Study Group) Arch Dermatol 2003 Dec;139(12):1563-70 PMID: 14676071 SCOPUS ID: 2-s2.0-0348134794 12/17/2003 90 Citations

Severe hidradenitis suppurativa treated with infliximab infusion. (Adams DR, Gordon KB, Devenyi AG, Ioffreda MD) Arch Dermatol 2003 Dec;139(12):1540-2 PMID: 14676068 SCOPUS ID: 2-s2.0-0348134795 12/17/2003 93 Citations

Evolution of biologic therapies for the treatment of psoriasis. (Gordon KB, McCormick TS) Skinmed 2003;2(5):286-94 PMID: 14673261 SCOPUS ID: 2-s2.0-2142747000 12/16/2003 9 Citations

CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. (Gottlieb AB, Casale TB, Frankel E, Goffe B, Lowe N, Ochs HD, Roberts JL, Washenik K, Vaishnaw AK, Gordon KB) J Am Acad Dermatol 2003 Nov;49(5):816-25 PMID: 14576659 SCOPUS ID: 2-s2.0-0142182716 10/25/2003 83 Citations

The immunology of psoriasis and biologic immunotherapy. (Mehlis SL, Gordon KB) J Am Acad Dermatol 2003 Aug;49(2 Suppl):S44-50 PMID: 12894125 SCOPUS ID: 2-s2.0-0042634230 08/02/2003 109 Citations

Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis. (Ortonne JP, Lebwohl M, Em Griffiths C, Alefacept Clinical Study Group) Eur J Dermatol 2003;13(2):117-23 PMID: 12695125 SCOPUS ID: 2-s2.0-0037359334 04/16/2003 63 Citations

Mouse immune system (Chan LS, Gordon KB) Animal Models of Human Inflammatory Skin Diseases 1 January 2003:119-140 SCOPUS ID: 2-s2.0-10844284103 01/01/2003 3 Citations

Evaluation of tissue-engineered skin (human skin substitute) and secondary intention healing in the treatment of full thickness wounds after Mohs micrographic or excisional surgery. (Gohari S, Gambla C, Healey M, Spaulding G, Gordon KB, Swan J, Cook B, West DP, Lapiere JC) Dermatol Surg 2002 Dec;28(12):1107-14; discussion 1114 PMID: 12472488 SCOPUS ID: 2-s2.0-0036950647 12/11/2002 61 Citations

Comparative tolerability of systemic treatments for plaque-type psoriasis. (McClure SL, Valentine J, Gordon KB) Drug Saf 2002;25(13):913-27 PMID: 12381213 SCOPUS ID: 2-s2.0-0036034028 10/17/2002 63 Citations

Biologic therapy for psoriasis: the new therapeutic frontier. (Singri P, West DP, Gordon KB) Arch Dermatol 2002 May;138(5):657-63 PMID: 12020229 SCOPUS ID: 2-s2.0-0036578797 05/22/2002 107 Citations

Differential abilities of central nervous system resident endothelial cells and astrocytes to serve as inducible antigen-presenting cells. (Girvin AM, Gordon KB, Welsh CJ, Clipstone NA, Miller SD) Blood 2002 May 15;99(10):3692-701 PMID: 11986225 SCOPUS ID: 2-s2.0-0037093239 05/03/2002 49 Citations

Safety of the new macrolide immunomodulators. (Robinson N, Singri P, Gordon KB) Semin Cutan Med Surg 2001 Dec;20(4):242-9 PMID: 11770911 SCOPUS ID: 2-s2.0-0035211541 01/05/2002 18 Citations

Chemoprevention of skin cancer. (Horn MA, Gordon KB) Cancer Treat Res 2001;106:255-82 PMID: 11225006 SCOPUS ID: 2-s2.0-0035234521 02/28/2001 2 Citations

Botulinum toxin type A for the treatment of axillary Hailey-Hailey disease. (Lapiere JC, Hirsh A, Gordon KB, Cook B, Montalvo A) Dermatol Surg 2000 Apr;26(4):371-4 PMID: 10759827 SCOPUS ID: 2-s2.0-0034030845 04/12/2000 74 Citations

In vivo gene therapy with interleukin-12 inhibits primary vascular tumor growth and induces apoptosis in a mouse model. (Wang C, Quevedo ME, Lannutti BJ, Gordon KB, Guo D, Sun W, Paller AS) J Invest Dermatol 1999 May;112(5):775-81 PMID: 10233771 SCOPUS ID: 2-s2.0-0032922137 05/08/1999 32 Citations

Dermatologic manifestations of gastrointestinal disorders. (Ward SK, Roenigk HH, Gordon KB) Gastroenterol Clin North Am 1998 Sep;27(3):615-36, vi PMID: 9891700 SCOPUS ID: 2-s2.0-0031728303 01/19/1999 19 Citations

Keratoacanthomas and lymphomatoid papulosis. (Guitart J, Gordon K) Am J Dermatopathol 1998 Aug;20(4):430-3 PMID: 9700388 SCOPUS ID: 2-s2.0-0031879746 08/13/1998 8 Citations

Fatal cytophagic histiocytic panniculitis after a short response to cyclosporine. (Guitart J, Sethi R, Gordon K) J Eur Acad Dermatol Venereol 1998 May;10(3):267-8 PMID: 9643334 SCOPUS ID: 2-s2.0-0031838681 06/27/1998 7 Citations

Presentation of proteolipid protein epitopes and B7-1-dependent activation of encephalitogenic T cells by IFN-gamma-activated SJL/J astrocytes. (Tan L, Gordon KB, Mueller JP, Matis LA, Miller SD) J Immunol 1998 May 01;160(9):4271-9 PMID: 9574529 SCOPUS ID: 2-s2.0-0032080658 05/09/1998 107 Citations

Expression of MHC class II and costimulatory molecules by endothelial cells of the blood brain barrier: Effect on antigen presentation (Girvin AM, Gordon KB, Tan L, Welsh J, Miller SD) FASEB Journal 20 March 1998;12(5) SCOPUS ID: 2-s2.0-33749341905 03/20/1998

Epitope spreading: lessons from autoimmune skin diseases. (Chan LS, Vanderlugt CJ, Hashimoto T, Nishikawa T, Zone JJ, Black MM, Wojnarowska F, Stevens SR, Chen M, Fairley JA, Woodley DT, Miller SD, Gordon KB) J Invest Dermatol 1998 Feb;110(2):103-9 PMID: 9457902 SCOPUS ID: 2-s2.0-0031882357 02/11/1998 308 Citations

Treatment of multiple lesions of Bowen disease with isotretinoin and interferon alfa. Efficacy of combination chemotherapy. (Gordon KB, Roenigk HH, Gendleman M) Arch Dermatol 1997 Jun;133(6):691-3 PMID: 9197821 SCOPUS ID: 2-s2.0-0030951868 06/01/1997 21 Citations

Treatment of refractory epidermolysis bullosa acquisita with extracorporeal photochemotherapy. (Gordon KB, Chan LS, Woodley DT) Br J Dermatol 1997 Mar;136(3):415-20 PMID: 9115929 SCOPUS ID: 2-s2.0-0031057403 03/01/1997 62 Citations

IFN-gamma-activated primary murine astrocytes express B7 costimulatory molecules and prime naive antigen-specific T cells. (Nikcevich KM, Gordon KB, Tan L, Hurst SD, Kroepfl JF, Gardinier M, Barrett TA, Miller SD) J Immunol 1997 Jan 15;158(2):614-21 PMID: 8992975 SCOPUS ID: 2-s2.0-0031568084 01/15/1997 140 Citations

The cutaneous manifestations of gastrointestinal disease. (Katz SK, Gordon KB, Roenigk HH) Prim Care 1996 Sep;23(3):455-76 PMID: 8888338 SCOPUS ID: 2-s2.0-0029792640 09/01/1996 12 Citations

Bowen's disease of the distal digit. Outcome of treatment with carbon dioxide laser vaporization. (Gordon KB, Garden JM, Robinson JK) Dermatol Surg 1996 Aug;22(8):723-8 PMID: 8780766 SCOPUS ID: 2-s2.0-0029743358 08/01/1996 51 Citations

Pseudo-mycosis fungoides in a patient taking clonazepam and fluoxetine. (Gordon KB, Guitart J, Kuzel T, Salard D, Bakouche O, Domer P, Roenigk H, Rosen S) J Am Acad Dermatol 1996 Feb;34(2 Pt 1):304-6 PMID: 8642101 SCOPUS ID: 2-s2.0-0030020717 02/01/1996 21 Citations

Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. (Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR, VonRoenn J) Cancer 1995 Apr 15;75(8):2169-73 PMID: 7697608 SCOPUS ID: 2-s2.0-0028943385 04/15/1995 154 Citations

Carbon dioxide laser vaporization for Bowen's disease of the finger. (Gordon KB, Robinson J) Arch Dermatol 1994 Oct;130(10):1250-2 PMID: 7944505 SCOPUS ID: 2-s2.0-0028073277 10/01/1994 16 Citations

Last update: 02/14/2024

© 2024 Clinical & Translational Science Institute
Medical College of Wisconsin
8701 Watertown Plank Road
Milwaukee, WI 53223

Publication and ontology data from NCBI | Disclaimer and Copyright

This site is a collaborative effort of the Medical College of Wisconsin and the Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number 2UL1TR001436) at the National Institutes of Health (NIH).

selective

Profiles for MCW, MU, MSOE, UWM, BCW, CW, Froedtert, and VA Faculty

Kenneth Brian Gordon MD

Chair, Professor

Publications (218)